KJT Welcomes Ellen Gordon, PhD

KJT Welcomes Ellen Gordon, PhD

KJT is thrilled to announce the newest addition to our Client Strategy team, Ellen Gordon, who will be joining us as a Senior Vice President of Client Strategy & Growth.

Ellen is an accomplished senior business development professional with extensive expertise in building and monetizing strategic relationships in the biopharmaceutical industry while delivering superior customer experiences. With a proven track record in identifying new business opportunities and capitalizing on them, Ellen brings a unique blend of subject matter expertise and business acumen to her role.

In her new position at KJT, Ellen will play a pivotal role in managing existing accounts while also spearheading new business development initiatives. Her strategic approach to client engagement and her ability to deliver value-added solutions align perfectly with KJT’s commitment to excellence and innovation.

Most recently, Ellen has been focused on delivering digital health and AI/ML solutions to pharmaceutical and biotech companies. Prior to joining KJT, Ellen was VP, Head of Business Development at Almaden Genomics, a platform company designed to streamline genomic workflows.  She also served as Vice President of Global Accounts at BrightInsight, a platform for biopharma and medtech regulated digital health solutions, Digital Ventures Lead for Memorial Sloan Kettering Cancer Center, and Executive Director of Business Development for GNS Healthcare.

Ellen holds a PhD in Political Science from the University of Michigan, an MA from Georgetown University, and a BA from Brandeis University.

“We are delighted to welcome Ellen to KJT. Ellen’s deep expertise and proven track record in sales will be invaluable as we continue to innovate and expand our reach in the healthcare sector. This addition underscores our commitment to attracting top talent and enhancing our capabilities to better serve our customers and improve patient outcomes. We look forward to the dynamic contributions Ellen will bring to our team,” said Michaela Gascon, President and CEO of KJT.

Blogs & News

Read More
Read More

Unlocking Participant Engagement: The Key to Meaningful Market Research

In pharmaceutical market research, one element remains consistently crucial: participant…

Read More
Read More

Navigating Successful Real-World Evidence Publications: An Interdisciplinary Journey

Publishing real-world evidence (RWE) research involves a comprehensive journey of strategic…

Read More
Read More

Go from Exam Room Conversations to Actionable Healthcare Insights

Understanding what goes on in the exam room between patients and HCPs remains a critical yet…

Read More
Read More

Patient Voice Isn’t Optional, It’s the Future of RWE

Real-world evidence (RWE) is only as meaningful as the perspectives it includes. While healthcare…

Read More
Read More

4 Use Cases for Augmenting Primary Data with Synthetic Data in Pharma Market Research

Synthetic data is not new to market research, and the healthcare insights industry is starting to…

Read More
Read More

Beyond the Hype: How Digital Twins Are Transforming Market Research

Digital twins are reshaping the way we generate insights across industries. In this webinar, we…

Read More
Read More

5 Takeaways from an Intellus Newbie

Having spent 25 years in the consumer research sector (finance, CPG, retail, tech, etc), I am used…

Read More
Read More

Reflections on PMRC 2025: The AI Train Left the Station… “Next Stop”

I have attended more than half of the PMRC conferences held over the past 16 years. Being a veteran…

Read More
Read More

10 Best Practices in Conducting Ethnography in Rare Disease Population

Rare disease patients face unique challenges that are often overlooked or misunderstood by those…

Read More
Read More

Building the Future: Why Qualitative Insights Will Thrive in the Age of AI

AI is transforming the way we collect and analyze qualitative data—but rather than replacing…

Let’s Take Research Further. Together.